David Brenner, M.D.
Dr. David Brenner is vice chancellor for health sciences and dean of the School of Medicine at the University of California, San Diego. In this role, he leads the School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California, San Diego, and UC San Diego Health. A distinguished physician-scientist and leader in the field of gastroenterological research, Dr. Brenner first joined UC San Diego Health System in 1985 as a gastroenterology fellow, later joining the School of Medicine faculty, and serving as a physician at Veterans Affairs (VA) San Diego Healthcare System. He also served as a Pew Scholar in the Biomedical Sciences and a Clinical Investigator in the VA system. In 1993, Dr. Brenner became professor and chief of the Division of Digestive Diseases and Nutrition at the University of North Carolina at Chapel Hill, where he continued to earn accolades for his patient care and research.
He was ultimately recruited to UC San Diego Health System from Columbia University Medical Center College of Physicians and Surgeons, where from 2003 to 2007 he was Samuel Bard Professor and chair of the Department of Medicine, a member of the Herbert Irving Comprehensive Cancer Center, a member of the Columbia University Institute of Nutrition, and physician-in-chief of New York Presbyterian Hospital/Columbia.
Dr. Brenner’s professional memberships include the American Society for Clinical Investigation; the Association of American Physicians, for which he is currently President-Elect; the American College of Physicians; the American Gastroenterological Association, and the American Clinical and Climatological Association. He is also on the board of directors of two philanthropic foundations, the AlphaOne Foundation and the Alcoholic Beverage Medical Research Foundation. Dr. Brenner has also been published numerous times and serves on several editorial boards.
He earned his medical degree from the Yale University School of Medicine. After completing his residency at Yale-New Haven Medical Center, he served as a research associate in the Genetics and Biochemistry Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).
Tatiana Kisseleva, M.D., Ph.D.
Tatiana Kisseleva obtained her M.D. and was trained as a liver surgeon at Russian University of Friendship (Moscow, Russia). She then studied biochemistry and immunology at Christian-Albrecht University (Kiel, Germany), where she received her Ph.D. Dr. Kisseleva was trained as a postdoctoral fellow at Columbia University, and later joined the University of California, San Diego faculty as an Assistant Professor of Surgery where she studies pathogenesis of liver fibrosis. The major interest of Dr. Kisseleva’s research is the characterization of the origin of fibrogenic myofibroblasts in fibrotic liver, and identification of new targets for anti-fibrotic therapy. Her recent studies have demonstrated that during regression of alcohol-induced liver fibrosis hepatic myofibroblasts inactivate, e.g. stop producing collagen Type I, and revert into a quiescent-like state. Characterization of the mechanism of myofibroblast inactivation may further advance our understanding of pathogenesis of liver fibrosis, and provide novel therapeutic approaches.
Stephen C. Strom, Ph.D.
Dr. Strom is a Professor in the department of laboratory medicine at Karolinska Institute in Stockholm, Sweden, where he leads translational research programs as the Director of Karolinska Institute’s Hepatology Program (KI-Hep) and holds the Sӧderberg Professorship in Regenerative Medicine. Dr. Strom completed his Ph.D. at the University of Kansas Medical Center in the department of pharmacology, and his post-doctoral training in genetic toxicology and carcinogenesis at Duke University Medical Center. Prior to joining Karolinska Institute in 2012, Dr. Strom held faculty positions at Duke University (1983-1987), the Medical College of Virginia (1988-1993), and the University of Pittsburgh (1993-2012). He is an expert in the isolation and study of human hepatocytes and a pioneer in the field of hepatocyte transplantation, having served as the Director for the first FDA-approved laboratory for clinical hepatocyte transplantation. Dr. Strom has authored over 240 peer reviewed publications and 21 book chapters and is a world-renowned expert in liver and hepatocyte biology. He currently serves on the Board of Councilors of the Cell Transplantation Society, for which he was the President from 2010-2013. He is the editor-in-chief of Transplantation Technology and the World Journal of Gastroenterology, and serves on the editorial board of numerous other journals focused on cell biology and transplantation. He has trained 4 Ph.D. students and 2 Master’s students, and served on the dissertation committee of 43 additional students.